Skip to main content

Orthocell heartened by US progression

09/05/2025 - 14:28

Bookmark

Save articles for future reference.

Orthocell boss Paul Anderson said the Murdoch-based biotech medical company is “well ahead” of its original targets in relation to US sales of its nerve repair product, Remplir.

X

To read our articles you will need to either login or subscribe.